1 active not recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Terminated 1 |
Follow SCID: new trials by email Literature Review of SCID trials Research Report on SCID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Conditioning SCID Infants Diagnosed Early Busulfan, Cell processing for TCRαβ+/CD19+ depletion - SCID | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 56 | 2018-10-22 | 2026-10-26 |
| JSP191 Antibody Targeting Conditioning in SCID Patients Humanized anti-CD117 Monoclonal Antibody (JSP191) - SCID | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 23 | 2017-03-20 | 2025-07-28 |
Immunologic Deficiency Syndromes (1)
Busulfan (1)
Center for International Blood and Marrow Transplant Research (1) · Jasper Therapeutics, Inc. (1)
United States (2) · Canada (1)
Christen L Ebens, M.D., MPH (1) · Christopher C. Dvorak, M.D. (1) · Elizabeth D Hicks, M.D. (1) · Harry L Malech, M.D. (1) · Joseph H. Oved, M.D. (1) · Michael Pulsipher, MD (1) · Neena Kapoor, M.D. (1) · Rajni A. Agarwal-Hashmi, M.D. (1) · Shanmuganathan Chandrakasan, M.D. (1) · Sharat Chandra, M.D. (1) · Sung-Yun Pai, MD (1) · Susan Prockop, M.D. (1) · Theodore B. Moore, M.D. (1)